GSK Trading Volume Surges 109.17% to 3.16 Billion, Stock Price Drops 3.84% Ranking 312th in Market

On June 13, 2025, GSK's trading volume reached 3.16 billion, marking a 109.17% increase from the previous day, ranking 312th in the day's stock market. GSK's stock price fell by 3.84%.

GSK's RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand its use in adults aged 18 and older. This move is significant as Arexvy was the first RSV vaccine approved in the European Economic Area for preventing lower respiratory tract disease caused by RSV in adults aged 60 and older, as well as those aged 50-59 who are at increased risk for RSV disease.

GSK anticipates a European regulatory decision during the first half of 2026 and is actively seeking expanded indications for its RSV vaccine in other countries, including the US and Japan. This regulatory review represents a crucial step in broadening the vaccine's reach to a wider adult population, potentially enhancing GSK's market position and revenue streams.